Antigua and Barbuda vs Maldives: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Antigua and Barbuda
0.2%
in 2024
Maldives
0.2%
in 2024
Antigua and Barbuda rank
98th
Maldives rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Antigua and Barbuda
- Maldives
How they compare
Antigua and Barbuda currently reports 0.2% against 0.2% in Maldives, a difference of 0.0%.
Across all 10 years both countries report, Maldives has been ahead every year.
Antigua and Barbuda ranks 98th and Maldives ranks 98th of 246 countries.
Maldives has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Antigua and Barbuda | Maldives | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.4% | 0.1% | Maldives |
| 2020s | 0.2% | 0.2% | 0.0% | Maldives |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Antigua and Barbuda or Maldives?
- Antigua and Barbuda, at 0.2% against 0.2% in Maldives as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Antigua and Barbuda and Maldives?
- 0.0%, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and Maldives?
- 10 years are reported by both, from 2015 to 2024.
- How do Antigua and Barbuda and Maldives rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Antigua and Barbuda ranks 98th and Maldives ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.